Sponsor Dossier
Reach Pharmaceuticals
Sponsor Dossier for Reach Pharmaceuticals. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: CAPTOPRIL
- Brand: CARBOPROST-REACH
- Brand: CYCLOPHOSPHAMIDE-REACH
- Brand: DEXRAZOXANE-REACH
- Brand: FOSAPREPITANT
- Brand: FUROSEMIDE-REACH
- Brand: METABOLICS
- Brand: MSN
About
Reach Pharmaceuticals is an Australian Private Company with ABN 25 623 897 183, registered in Victoria. The company is active and registered for GST from 1 July 2020.
Portfolio
Reach Pharmaceuticals has 12 brands on the ARTG, of which 11 are indexable and 10 carry a Product Information document. 4 brands are PBS-listed, 2 have a PBAC outcome on record, and 2 have an AusPAR on record. Notable brands include CAPTOPRIL, CARBOPROST-REACH, CYCLOPHOSPHAMIDE-REACH, DEXRAZOXANE-REACH, FOSAPREPITANT, FUROSEMIDE-REACH, METABOLICS, MSN, NELARABINE-REACH, ROMIDEPSIN-REACH, SODIUM, THIOTEPA-REACH.
Therapeutic focus
— Oncology: 7 brands — Cardiology: 2 brands — Complementary Medicine: 1 brand — Reproductive Health: 1 brand — Neurology: 1 brand
PBS footprint
4 brands are PBS-listed, with the latest PBS schedule date 2026-10-01.
Regulatory activity
The latest PBAC outcome is 2026-03-01, across 2 brands with a PBAC outcome on record. The latest AusPAR is 2025-10-14, across 2 brands with an AusPAR on record.